DE602005013568D1 - Antitumor-kombinationen mit vegf-trap und 5fu oder einem seiner derivate - Google Patents

Antitumor-kombinationen mit vegf-trap und 5fu oder einem seiner derivate

Info

Publication number
DE602005013568D1
DE602005013568D1 DE602005013568T DE602005013568T DE602005013568D1 DE 602005013568 D1 DE602005013568 D1 DE 602005013568D1 DE 602005013568 T DE602005013568 T DE 602005013568T DE 602005013568 T DE602005013568 T DE 602005013568T DE 602005013568 D1 DE602005013568 D1 DE 602005013568D1
Authority
DE
Germany
Prior art keywords
vegf
trap
derivatives
combinations
antitumor combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005013568T
Other languages
German (de)
English (en)
Inventor
Patricia Vrignaud
Marielle Chiron-Blondel
Marie-Christine Bissery
Eric Furfine
Jocelyn Holash
Jesse M Cedarbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005013568(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of DE602005013568D1 publication Critical patent/DE602005013568D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602005013568T 2004-12-03 2005-12-02 Antitumor-kombinationen mit vegf-trap und 5fu oder einem seiner derivate Expired - Lifetime DE602005013568D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0412870A FR2878749B1 (fr) 2004-12-03 2004-12-03 Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
PCT/FR2005/003005 WO2006059012A1 (fr) 2004-12-03 2005-12-02 Combinaisons antitumorales contenant un agent inhibiteur de vegf et du 5fu ou un de ses derives

Publications (1)

Publication Number Publication Date
DE602005013568D1 true DE602005013568D1 (de) 2009-05-07

Family

ID=34954452

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005013568T Expired - Lifetime DE602005013568D1 (de) 2004-12-03 2005-12-02 Antitumor-kombinationen mit vegf-trap und 5fu oder einem seiner derivate

Country Status (25)

Country Link
US (3) US20060178305A1 (https=)
EP (1) EP1824504B1 (https=)
JP (1) JP4980236B2 (https=)
KR (1) KR101313404B1 (https=)
CN (1) CN101068564B (https=)
AT (1) ATE426409T1 (https=)
AU (1) AU2005311191C1 (https=)
BR (1) BRPI0518700B8 (https=)
CA (1) CA2586735C (https=)
CY (3) CY1109181T1 (https=)
DE (1) DE602005013568D1 (https=)
DK (1) DK1824504T3 (https=)
ES (1) ES2324233T3 (https=)
FR (3) FR2878749B1 (https=)
HR (1) HRP20090336T1 (https=)
IL (1) IL183481A (https=)
LU (2) LU92202I2 (https=)
ME (1) ME01706B (https=)
MX (1) MX2007006607A (https=)
PL (1) PL1824504T3 (https=)
PT (1) PT1824504E (https=)
RS (1) RS50769B (https=)
RU (1) RU2384344C2 (https=)
SI (1) SI1824504T1 (https=)
WO (1) WO2006059012A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
JO3283B1 (ar) * 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR102486321B1 (ko) 2014-07-18 2023-01-09 사노피 암을 앓고 있는 것으로 의심되는 환자를 아플리베르셉트로 치료한 결과를 예측하는 방법
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
EP3246029A1 (en) * 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN115197948A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-VEGF-Trap、其基因组、制备方法及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9701081D0 (en) * 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CN100523187C (zh) * 1999-06-08 2009-08-05 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo

Also Published As

Publication number Publication date
MX2007006607A (es) 2007-07-25
ME01706B (me) 2010-08-31
BRPI0518700B1 (pt) 2020-02-11
AU2005311191A1 (en) 2006-06-08
WO2006059012A1 (fr) 2006-06-08
EP1824504A1 (fr) 2007-08-29
FR13C0024I1 (fr) 2013-05-24
PT1824504E (pt) 2009-06-25
US20130184205A1 (en) 2013-07-18
US20090285841A1 (en) 2009-11-19
BRPI0518700B8 (pt) 2021-05-25
EP1824504B1 (fr) 2009-03-25
KR101313404B1 (ko) 2013-10-01
IL183481A0 (en) 2007-09-20
HRP20090336T1 (hr) 2009-07-31
CA2586735A1 (fr) 2006-06-08
AU2005311191B2 (en) 2011-12-08
FR13C0025I1 (fr) 2013-05-24
LU92203I2 (fr) 2013-11-15
US8388963B2 (en) 2013-03-05
FR2878749A1 (fr) 2006-06-09
LU92202I9 (https=) 2019-01-15
DK1824504T3 (da) 2009-07-20
LU92202I2 (fr) 2013-11-15
IL183481A (en) 2013-09-30
HK1114769A1 (en) 2008-11-14
FR2878749B1 (fr) 2007-12-21
CA2586735C (fr) 2014-08-12
RU2007123607A (ru) 2009-01-10
ES2324233T3 (es) 2009-08-03
US20060178305A1 (en) 2006-08-10
CY2013018I1 (el) 2020-05-29
ATE426409T1 (de) 2009-04-15
CN101068564A (zh) 2007-11-07
RU2384344C2 (ru) 2010-03-20
BRPI0518700A2 (pt) 2008-12-02
JP2008521866A (ja) 2008-06-26
JP4980236B2 (ja) 2012-07-18
PL1824504T3 (pl) 2009-08-31
CY2013017I1 (el) 2014-07-02
RS50769B (sr) 2010-08-31
CY1109181T1 (el) 2014-07-02
KR20070091130A (ko) 2007-09-07
AU2005311191C1 (en) 2015-04-30
SI1824504T1 (sl) 2009-08-31
LU92203I9 (https=) 2019-01-15
CN101068564B (zh) 2010-12-15

Similar Documents

Publication Publication Date Title
LU92203I2 (fr) Aflibercept en combination avec 5-FU
NZ752526A (en) Pyrrolobenzodiazepine conjugates
CL2008002006A1 (es) Compuestos derivados de morfolin pirimidina, composicion farmaceutica, y su uso como inhibidores de la m-tor-quinasa para el tratamiento de l a inflamacion, cancer, enfermedades inmunes, enfermedad obstructiva pulmonar, enfermedad cardiovascular.
CY1111121T1 (el) Ετεροαρυλο ενωσεις χρησιμες ως αναστολεις ενζυμων ενεργοποiησης ε1
DE602005027707D1 (de) Isoindolin-verbindungen und deren verwendungen
DK1951729T3 (da) Oxygenbundne pyrimidinderivater
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
PL2526934T4 (pl) Inhibitory kinazy tyrozynowej Brutona
EA200870019A1 (ru) Лактамовые соединения и способы их применения
ATE469658T1 (de) Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
NO20075074L (no) Kinazolinon T-type-kalsiumkanalantagonister
ATE448232T1 (de) Substituierte heterozyklen
NO20070580L (no) Behandling av cancer.
ECSP055669A (es) Derivados de pirimidinona como agentes terapéuticos contra procesos de remodelación, isquemicos e inflamatorios agudos y cronicos
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση
UY28517A1 (es) Nueva combinación
TW200722098A (en) Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in pharmaceutical compositions for treating cancer
MX2024014771A (es) Terapia combinada
ATE478847T1 (de) Substituierte pyridylmethylbicyclocarboxyamidverbindungen
ATE508750T1 (de) Derivate von vitamin d und ihre verwendung in der therapie
WO2007012967A3 (en) Combination of voriconazole and fluconazole

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R065 Request for grant of supplementary protection certificate validly filed

Free format text: PRODUCT NAME: AFLIBERCEPT IN KOMBINATION MIT 5-FLUOROURACIL; REGISTRATION NO/DATE: EU/1/12/814/001-003 20130201

Spc suppl protection certif: 122013000037

Filing date: 20130419

Expiry date: 20251203

Effective date: 20130508

Free format text: PRODUCT NAME: AFLIBERCEPT; REGISTRATION NO/DATE: EU/1/12/814/001-003 20130201

Spc suppl protection certif: 122013000038

Filing date: 20130419

Expiry date: 20251203

Effective date: 20130508